Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teratogenic Drugs Pose Little Risk To Partners Of Male Patients, FDA Panel Says

Jan 14 2013

• By Cathy Dombrowski

Related Content

To REMS Or Not To REMS? <em>Erivedge </em>Shows Division At FDA Over Oncology Risk Management

Nov 01 2012

Prostate Cancer Prevention Endpoint May Have Been Key Problem As ODAC Votes Down BPH sNDAs

Dec 13 2010

Related Companies

Genentech, Inc.

Merck & Co., Inc.

Additional Topics

United States Regulation Risk Management Post Market Regulation & Studies Safety Advisory Committees BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window